Patents Examined by Brian Hartnett
-
Patent number: 11203646Abstract: The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3?), as well as methods of making and using these anti-CD3? antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: March 14, 2019Date of Patent: December 21, 2021Assignee: NovImmune SAInventors: Nicolas Fischer, Giovanni Magistrelli, Franck Gueneau, Ulla Ravn
-
Patent number: 11198737Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y177 mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.Type: GrantFiled: April 16, 2021Date of Patent: December 14, 2021Assignee: McMaster UniversityInventors: Christopher W. Helsen, Jonathan Bramson, Anna Dvorkin-Gheva, Galina F. Denisova, Ksenia Bezverbnaya, Kenneth Anthony Mwawasi
-
Patent number: 11180553Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds human CD22, having an antigen-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—NYWIH (SEQ ID No. 1); CDR2—GINPGNNYATYRRKFQG (SEQ ID No. 2) CDR3—EGYGNYGAWFAY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—RSSQSLANSYGNTFLS (SEQ ID No. 4); CDR2—GISNRFS (SEQ ID No. 5) CDR3—LQGTHQPYT (SEQ ID No. 6). The present invention also provides a cell comprising such a CAR and the use of such a cell to treat cancer.Type: GrantFiled: June 15, 2017Date of Patent: November 23, 2021Assignee: AUTOLUS LIMITEDInventors: Shimobi Onuoha, Martin Pulé, Simon Thomas, Shaun Cordoba, Evangelia Kokalaki
-
Patent number: 11161908Abstract: Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided.Type: GrantFiled: June 6, 2017Date of Patent: November 2, 2021Assignees: City of Hope, Board of Regents, The University of Texas SystemInventors: Hong Qin, Larry W. Kwak
-
Patent number: 11136401Abstract: Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.Type: GrantFiled: March 25, 2016Date of Patent: October 5, 2021Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Peisheng Hu, Jacek K. Pinski
-
Patent number: 11124568Abstract: The present invention relates to the use of anti-CD3 and anti-CD25 antibodies for the management and treatment of inflammatory diseases and psycho-immune disorders, such as depression, autism (ASD) and attention deficit/hyperactivity disorder (ADHD).Type: GrantFiled: August 19, 2020Date of Patent: September 21, 2021Assignee: Vitruviae LLCInventors: Mahiuddin Ahmed, Sonia Sequeira
-
Patent number: 11124767Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).Type: GrantFiled: October 19, 2018Date of Patent: September 21, 2021Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: David Peritt, Kim Campbell, Amy Krutsick
-
Patent number: 11098093Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.Type: GrantFiled: January 13, 2020Date of Patent: August 24, 2021Assignee: Shattuck Labs, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 11077178Abstract: A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.Type: GrantFiled: September 20, 2017Date of Patent: August 3, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The United States Government as represented by the Department of Veterans AffairsInventors: Liyanage Parakrama Perera, Thomas Alexander Waldmann, Kevin Charles Conlon, Pin-Yu Perera
-
Patent number: 11026973Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.Type: GrantFiled: March 23, 2020Date of Patent: June 8, 2021Assignee: Myeloid Therapeutics, Inc.Inventors: Daniel Getts, Yuxiao Wang
-
Patent number: 11013764Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.Type: GrantFiled: March 23, 2020Date of Patent: May 25, 2021Assignee: Myeloid Therapeutics, Inc.Inventors: Daniel Getts, Yuxiao Wang
-
Patent number: 11013765Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: December 16, 2019Date of Patent: May 25, 2021Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 10995153Abstract: The present invention relates to a novel polypeptide that binds selectively to mouse or rabbit immunoglobulin G. More specifically, the present invention relates to a polypeptide that binds to mouse or rabbit immunoglobulin G, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a transformant introduced with the expression vector, a method of producing the polypeptide using the transformant, and a composition for immunoassay comprising the polypeptide. The novel peptide according to the present invention binds specifically to mouse or rabbit immunoglobulin G, can replace conventional expensive secondary immunoglobulin G, and can be used in various biological immunoassays. In addition, a conjugate of the polypeptide of the present invention and immunoglobulin G is useful for fabrication of various immunosensors/immunochips and for drug screening.Type: GrantFiled: September 20, 2016Date of Patent: May 4, 2021Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hak-Sung Kim, Sukyo Jeong, Woosung Heu, Jong-Won Kim, Joong-Jae Lee
-
Patent number: 10988517Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.Type: GrantFiled: June 3, 2020Date of Patent: April 27, 2021Assignee: Shattuck Labs, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 10941192Abstract: Provided is a VHH antibody including an amino acid sequence in which at least one selected from the group consisting of glycine in position 36, arginine in position 50, and glycine in position 78, on the basis of IMGT numbering, of the amino acid sequence represented by SEQ ID NO: 1 is substituted with another amino acid. The VHH antibody according to the present disclosure is thermostable.Type: GrantFiled: April 2, 2019Date of Patent: March 9, 2021Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.Inventors: Emina Ikeuchi, Jin Muraoka
-
Patent number: 10858435Abstract: Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.Type: GrantFiled: June 25, 2020Date of Patent: December 8, 2020Assignee: ULTRAHUMAN NINE LIMITEDInventor: William James Jonathan Finlay
-
Patent number: 10858434Abstract: Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.Type: GrantFiled: June 25, 2020Date of Patent: December 8, 2020Assignee: ULTRAHUMAN EIGHT LIMITEDInventor: William James Jonathan Finlay